Intuitive Surgical, Inc. Q1 2026 Earnings Call Summary

Total procedure growth of 17% was driven by broad-based adoption of da Vinci and Ion platforms, with da Vinci 5 utilization notably exceeding that of the Xi model.

U.S. growth was bolstered by a 31% increase in after-hours procedures and higher overall utilization, particularly in general surgery and benign gynecology.

International expansion remains a core pillar, with OUS procedures now representing 38% of total volume, up from 25% a decade ago, despite headwinds in China and Japan.

The da Vinci 5 ecosystem is capturing high-fidelity surgical data at scale, providing the foundation for a long-term digital road map focused on AI-enabled decision support and future automation.

Management attributes margin strength to fixed-cost leverage and product cost reductions, with da Vinci 5 achieving contribution margins comparable to the mature Xi platform.

Strategic investments in market access and clinical evidence are yielding favorable policy shifts, such as new reimbursements for seven additional procedures in Japan effective June 2026.

Full-year 2026 procedure growth guidance was raised to 13.5%–15.5%, assuming continued strength in U.S. general surgery and international non-urology adoption.

The financial outlook assumes potential headwinds from the expiration of ACA premium subsidies, ongoing capital pressure in Europe, and competitive pricing in China.

Force Feedback instrumentation adoption is expected to progress steadily through 2026 following recent FDA 510(k) clearance for expanded clinical uses.

Gross margin guidance of 67.5%–68.5% accounts for a 100 basis point impact from tariffs and anticipated increases in freight and semiconductor memory costs.

Management expects to drive ‘innovation-led revenue growth’ by sharing value from differentiated products like da Vinci 5 and SP while offering cost-effective solutions like refurbished Xi systems in sensitive segments.

A Q1 cyber incident resulted in unauthorized access to certain customer and corporate data, though management confirmed no disruption to business operations or product safety.

The bariatric procedure segment in the U.S. declined approximately 10%, continuing to be impacted by the increased use of GLP-1 medications for obesity management.

China remains a challenging environment due to low tender activity, domestic competition, and policy-driven pricing pressure, with reimbursement clarity not expected until 2027.

The company completed a leadership transition with Dr. Jamie Wong promoted to Chief Medical Officer following the retirement of Dr. Myriam Curet.